Myovant Plans Q4 Uterine Fibroid Drug Filing In A Showdown With AbbVie

A second Phase III trial testing relugolix met its primary endpoint, putting Myovant in a tight race with AbbVie to bring the first drug to market for women with uterine fibroids.